Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer

Investigators demonstrated that CBX3 was abnormally upregulated in CDK4/6 inhibitors-resistant cells, and that CBX3 was almost positively correlated with the cell cycle in multiple malignancies and was downregulated by BET inhibitors.